Back to Annual Meeting ePosters

BACKGROUND - We hypothesized that a low-volume (100ml), single-shot cristalloid cardioplegic strategy (with CARDIOPLEXOL) avoiding hemodilution is safe to use in isolated aortic valve replacement.
METHODS - 76 consecutive patients undergoing elective isolated aortic valve replacement at a single institution were included in the study.
RESULTS - CARDIOPLEXOL resulted in immediate cardiac arrest. Intraoperative courses were uneventful. No further CARDIOPLEXOL was administered throughout the procedure. Correlation between postoperative maximum Troponin T concentrations and CK-MB concentrations, respectively, and the aortic cross-clamp time were significant (P=0.003, P=0.05). A multivariate logistic regression model for maximum postoperative Troponin T concentrations (>0.9 µg/l) revealed a significant prognostic effect only for aortic cross-clamp time (P=0.007, OR 1.109, CI95% 1.006-1.212); a trend was seen with the logistic Euroscore (P=0.06, OR 1.124, CI95% 1.007-1.241). All patients with Troponin T concentrations >0.9 µg/l had an aortic cross-clamp time over 60 minutes. Mortality 30 days after surgery was 4% (predicted with the logistic Euroscore mean 9.7%), one patient died due to right heart failure, and two patients non-cardiac related.
CONCLUSIONS - The use of low-volume, single-shot CARDIOPLEXOL seems to be safe for patients undergoing isolated AVR. This approach simplifies and speeds up the procedure.